Improvement of endothelial dysfunction as a surrogate endpoint in the treatment of hypertension.
Santoso
T
T
Division of Cardiology, Department of Internal Medicine, University of Indonesia Medical School, Jakarta, Indonesia. tsantoso@cbn.net.id
D000804:Angiotensin II / Q000502:physiology; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D003952:Diagnostic Imaging; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D016328:NF-kappa B / Q000502:physiology; D009569:Nitric Oxide / Q000494:pharmacology / Q000502:physiology; D014652:Vascular Diseases / Q000175:diagnosis / Q000503:physiopathology; D014655:Vascular Resistance / Q000187:drug effects; D014662:Vasoconstrictor Agents; D014664:Vasodilation / Q000502:physiology; D014665:Vasodilator Agents / Q000494:pharmacology
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D016328:NF-kappa B; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D000804:Angiotensin II; D009569:Nitric Oxide